T. Rowe Price Investment Management
KRYS icon

T. Rowe Price Investment Management’s Krystal Biotech KRYS Stock Holding History

T. Rowe Price Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-185,550
Closed -$33.5M – 714
2025
Q1 		$33.5M Buy
+185,550
New +$31.2M 0.02% 450

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Investment Management's KRYS Position: Q2 2025 in Review

T. Rowe Price Investment Management sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 185,550 shares — an estimated $33.5M sold.

T. Rowe Price Investment Management first reported a position in KRYS in Q1 2025 and held it in 1 quarter. The position peaked at $33.5M in Q1 2025. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • T. Rowe Price Investment Management reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 185,550 Krystal Biotech shares in Q2 2025, an estimated $33.5M.
  • T. Rowe Price Investment Management first reported a position in Krystal Biotech in Q1 2025 and held it in 1 quarter.
  • T. Rowe Price Investment Management's Krystal Biotech position peaked at $33.5M in Q1 2025.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.